688221 Stock Overview
A commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patient health. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Frontier Biotechnologies Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥7.43 |
| 52 Week High | CN¥11.29 |
| 52 Week Low | CN¥4.48 |
| Beta | 0.81 |
| 11 Month Change | 19.07% |
| 3 Month Change | 50.40% |
| 1 Year Change | -34.01% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -45.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688221 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 2.5% | -2.6% | -2.1% |
| 1Y | -34.0% | -20.9% | 2.8% |
Return vs Industry: 688221 underperformed the CN Biotechs industry which returned -20.9% over the past year.
Return vs Market: 688221 underperformed the CN Market which returned 2.8% over the past year.
Price Volatility
| 688221 volatility | |
|---|---|
| 688221 Average Weekly Movement | 9.5% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 688221 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688221's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 395 | C. J. Wang | www.frontierbiotech.com |
Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patient health. The company’s medicines address the unmet medical needs of patients in the areas of anti-HIV treatment and pain management. It offers Aikening, a long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS.
Frontier Biotechnologies Inc. Fundamentals Summary
| 688221 fundamental statistics | |
|---|---|
| Market cap | CN¥2.78b |
| Earnings (TTM) | -CN¥279.96m |
| Revenue (TTM) | CN¥133.67m |
20.8x
P/S Ratio-9.9x
P/E RatioIs 688221 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688221 income statement (TTM) | |
|---|---|
| Revenue | CN¥133.67m |
| Cost of Revenue | CN¥84.16m |
| Gross Profit | CN¥49.51m |
| Other Expenses | CN¥329.47m |
| Earnings | -CN¥279.96m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Nov 25, 2024
| Earnings per share (EPS) | -0.75 |
| Gross Margin | 37.04% |
| Net Profit Margin | -209.43% |
| Debt/Equity Ratio | 39.0% |
How did 688221 perform over the long term?
See historical performance and comparison